Court rules against Elan in Tysabri dispute with Biogen

09/4/2009 | Wall Street Journal, The

A federal judge ruled that Elan must amend its marketing deal with Johnson & Johnson for multiple sclerosis drug Tysabri because it violates Elan's partnership with Biogen Idec on the product. The dispute stems from J&J's purchase of a stake in Elan that gives J&J an option to finance Elan's purchase of Tysabri rights owned by Biogen.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX